These findings establish SGLT2 inhibitors as promising therapeutic candidates for Alzheimer's disease by modulating microglial metabolism to promote Aβ clearance and alleviate neurodegeneration. Here, SLC5A2 is linked to early-onset autosomal dominant Alzheimer disease.